II 

115TH CONGRESS 

1ST SESSION S. 1369 

To amend the Internal Revenue Code of 1986 to establish an excise tax 

on certain prescription drugs which have been subject to a price spike, 

and for other purposes. 

IN THE SENATE OF THE UNITED STATES 

JUNE 15, 2017 

Mr. BROWN (for himself, Mrs. GILLIBRAND, Mr. FRANKEN, Mr. REED, Ms. 

HASSAN, and Mr. UDALL) introduced the following bill; which was read 

twice and referred to the Committee on Finance 

A BILL 

To amend the Internal Revenue Code of 1986 to establish 

an excise tax on certain prescription drugs which have 

been subject to a price spike, and for other purposes. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Stop Price Gouging 

5 Act’’. 

6 SEC. 2. IDENTIFICATION OF PRESCRIPTION DRUG PRICE 

7 SPIKES. 

8 (a) DEFINITIONS.—In this section: 


lotter on DSKBCFDHB2PROD with BILLS
2 

•S 1369 IS

1 (1) APPLICABLE ENTITY.—The term ‘‘applica2 ble entity’’ means the holder of an application ap3 proved under subsection (c) or (j) of section 505 of 

4 the Federal Food, Drug, and Cosmetic Act (21 

5 U.S.C. 355) or of a license issued under subsection 

6 (a) or (k) of section 351 of the Public Health Serv7 ice Act (42 U.S.C. 262) for a drug described in 

8 paragraph (5)(A). 

9 (2) AVERAGE MANUFACTURER PRICE.—The 

10 term ‘‘average manufacturer price’’— 

11 (A) has the same meaning given such term 

12 under section 1927(k)(1) of the Social Security 

13 Act (42 U.S.C. 1396r–8(k)(1)); or 

14 (B) with respect to a drug for which there 

15 is no average manufacturer price as so defined, 

16 such term shall mean the wholesale acquisition 

17 cost of the drug. 

18 (3) COMMERCE.—The term ‘‘commerce’’ has 

19 the meaning given such term in section 4 of the 

20 Federal Trade Commission Act (15 U.S.C. 44). 

21 (4) INSPECTOR GENERAL.—The term ‘‘Inspec22 tor General’’ means the Inspector General of the De23 partment of Health and Human Services. 

24 (5) PRESCRIPTION DRUG.— 


lotter on DSKBCFDHB2PROD with BILLS
3 

•S 1369 IS

1 (A) IN GENERAL.—The term ‘‘prescription 

2 drug’’ means any drug (as defined in section 

3 201(g) of the Federal Food, Drug, and Cos4 metic Act (21 U.S.C. 321(g))), including a com5 bination product whose primary mode of action 

6 is determined under section 503(g) of such Act 

7 (21 U.S.C. 353(g)) to be that of a drug, and 

8 that— 

9 (i) is subject to section 503(b)(1) of 

10 the Federal Food, Drug, and Cosmetic Act 

11 (21 U.S.C. 353(b)(1)); and 

12 (ii) is covered by a Federal health 

13 care program (as defined in section 

14 1128B(f) of the Social Security Act (42 

15 U.S.C. 1320a–7b(f))). 

16 (B) TREATMENT OF REFORMULATED

17 DRUGS.—For purposes of this section, a pre18 scription drug with respect to which the Sec19 retary of Health and Human Services has ap20 proved any minor reformulation that does not 

21 produce a meaningful therapeutic benefit, the 

22 drug that was approved prior to any such refor23 mulation and the drug with any such reformu24 lation shall be considered one prescription drug. 

25 (6) PRICE SPIKE.— 


lotter on DSKBCFDHB2PROD with BILLS
4 

•S 1369 IS

1 (A) IN GENERAL.—The term ‘‘price spike’’ 

2 means an increase in the average manufacturer 

3 price in commerce of a prescription drug for 

4 which the price spike percentage is equal to or 

5 greater than applicable price increase allowance. 

6 (B) PRICE SPIKE PERCENTAGE.—The 

7 price spike percentage is the percentage (if any) 

8 by which— 

9 (i) the average manufacturer price of 

10 a prescription drug in commerce for the 

11 calendar year; exceeds 

12 (ii) the average manufacturer price of 

13 such prescription drug in commerce for the 

14 calendar year preceding such year. 

15 (C) APPLICABLE PRICE INCREASE ALLOW16 ANCE.—The applicable price increase allowance 

17 for any calendar year is the percentage (round18 ed to the nearest one-tenth of 1 percent) by 

19 which the medical care consumer price index 

20 detailed expenditure category for all urban con21 sumers (United States city average) for that 

22 year exceed such index for the preceding cal23 endar year. 

24 (7) PRICE SPIKE REVENUE.— 


lotter on DSKBCFDHB2PROD with BILLS
5 

•S 1369 IS

1 (A) IN GENERAL.—The price spike revenue 

2 for any calendar year is an amount equal to— 

3 (i) the gross price spike revenue, 

4 minus 

5 (ii) the adjustment amount. 

6 (B) GROSS PRICE SPIKE REVENUE.—The 

7 gross price spike revenue for any calendar year 

8 is an amount equal to the product of— 

9 (i) an amount equal to the difference 

10 between clause (i) of paragraph (6)(B) and 

11 clause (ii) of such paragraph; and 

12 (ii) the total number of units of the 

13 prescription drug which were sold in com14 merce in such calendar year. 

15 (C) ADJUSTMENT AMOUNT.—The adjust16 ment amount is the amount, if any, of the gross 

17 price spike revenue which the Inspector General 

18 has determined is due solely to an increase in 

19 the cost of the inputs necessary to manufacture 

20 the prescription drug subject to the price spike. 

21 (b) SUBMISSION BY PHARMACEUTICAL COMPANIES

22 OF INFORMATION TO INSPECTOR GENERAL.— 

23 (1) IN GENERAL.—For each prescription drug, 

24 the applicable entity shall submit to the Inspector 


lotter on DSKBCFDHB2PROD with BILLS
6 

•S 1369 IS

1 General a quarterly report that includes the fol2 lowing: 

3 (A) For each prescription drug of the ap4 plicable entity— 

5 (i) the total number of units of the 

6 prescription drug which were sold in com7 merce in the preceding calendar quarter; 

8 (ii) the average and median price per 

9 unit of such prescription drug in commerce 

10 in the preceding calendar quarter, 

11 disaggregated by month; and 

12 (iii) the gross revenues from sales of 

13 such prescription drug in commerce in the 

14 preceding calendar quarter. 

15 (B) Such information related to increased 

16 input costs or public health considerations as 

17 the applicable entity may wish the Inspector 

18 General to consider in making a determination 

19 under clause (ii) of subsection (c)(2)(B) or an 

20 assessment in clause (iii) of such subsection for 

21 the preceding calendar quarter. 

22 (C) Such information related to any antici23 pated increased input costs for the subsequent 

24 calendar quarter as the applicable entity may 

25 wish the Inspector General to consider in makVerDate Sep 11 2014 03:49 Jun 20, 2017 Jkt 069000 PO 00000 Frm 00006 Fmt 6652 Sfmt 6201 E:\BILLS\S1369.IS S1369

lotter on DSKBCFDHB2PROD with BILLS
7 

•S 1369 IS

1 ing a determination under clause (ii) of sub2 section (c)(2)(B) or an assessment in clause 

3 (iii) of such subsection for such calendar quar4 ter. 

5 (2) PENALTY FOR FAILURE TO SUBMIT.— 

6 (A) IN GENERAL.—An applicable entity de7 scribed in paragraph (1) that fails to submit in8 formation to the Inspector General regarding a 

9 prescription drug, as required by such para10 graph, before the date specified in paragraph 

11 (3) shall be liable for a civil penalty, as deter12 mined under subparagraph (B). 

13 (B) AMOUNT OF PENALTY.—The amount 

14 of the civil penalty shall be equal to the product 

15 of— 

16 (i) an amount, as determined appro17 priate by the Inspector General, which is— 

18 (I) not less than 0.5 percent of 

19 the gross revenues from sales of the 

20 prescription drug described in sub21 paragraph (A) for the preceding cal22 endar year, and 

23 (II) not greater than 1 percent of 

24 the gross revenues from sales of such 


lotter on DSKBCFDHB2PROD with BILLS
8 

•S 1369 IS

1 prescription drug for the preceding 

2 calendar year, and 

3 (ii) the number of days in the period 

4 between— 

5 (I) the applicable date specified 

6 in paragraph (3), and 

7 (II) the date on which the In8 spector General receives the informa9 tion described in paragraph (1) from 

10 the applicable entity. 

11 (3) SUBMISSION DEADLINE.—An applicable en12 tity shall submit each quarterly report described in 

13 paragraph (1) not later than January 17, April 18, 

14 June 15, and September 15 of each calendar year. 

15 (c) ASSESSMENT BY INSPECTOR GENERAL.— 

16 (1) IN GENERAL.—Not later than the last day 

17 in February of each year, the Inspector General, in 

18 consultation with other relevant Federal agencies 

19 (including the Federal Trade Commission), shall— 

20 (A) complete an assessment of the infor21 mation the Inspector General received pursuant 

22 to subsection (b)(1) with respect to sales of pre23 scription drugs in the preceding calendar year; 

24 and 


lotter on DSKBCFDHB2PROD with BILLS
9 

•S 1369 IS

1 (B) in the case of any prescription drug 

2 which satisfies the conditions described in para3 graph (1) or (2) of subsection (d), submit a rec4 ommendation to the Secretary of Health and 

5 Human Services that such drug be exempted 

6 from application of the tax imposed under sec7 tion 4192 of the Internal Revenue Code of 1986 

8 (as added by section 3 of this Act) for such 

9 year. 

10 (2) ELEMENTS.—The assessment required by 

11 paragraph (1)(A) shall include the following: 

12 (A) Identification of each price spike relat13 ing to a prescription drug in the preceding cal14 endar year. 

15 (B) For each price spike identified under 

16 subparagraph (A)— 

17 (i) a determination of the price spike 

18 revenue; 

19 (ii) a determination regarding the ac20 curacy of the information submitted by the 

21 applicable entity regarding increased input 

22 costs; and 

23 (iii) an assessment of the rationale of 

24 the applicable entity for the price spike. 

25 (d) EXEMPTION OF CERTAIN DRUGS.— 


lotter on DSKBCFDHB2PROD with BILLS
10 

•S 1369 IS

1 (1) IN GENERAL.—The Secretary of Health and 

2 Human Services, upon recommendation of the In3 spector General pursuant to subsection (c)(1)(B), 

4 may exempt any prescription drug which has been 

5 subject to a price spike during the preceding cal6 endar year from application of the tax imposed 

7 under section 4192 of the Internal Revenue Code of 

8 1986 for such year, if the Secretary determines 

9 that— 

10 (A) based on information submitted pursu11 ant to subsection (b)(1)(B), a for-cause price 

12 increase exemption should apply; or 

13 (B)(i) the prescription drug which has 

14 been subject to a price spike has an average 

15 manufacturer price of not greater than $10 for 

16 a 30 day supply; and 

17 (ii) such drug is marketed by not less than 

18 3 other holders of applications approved under 

19 subsection (c) or (j) of section 505 of the Fed20 eral Food, Drug, and Cosmetic Act (21 U.S.C. 

21 355), where such applications approved under 

22 such subsection (j) use as a reference drug the 

23 drug so approved under such subsection (c). 


lotter on DSKBCFDHB2PROD with BILLS
11 

•S 1369 IS

1 (2) CLARIFICATION.—In considering, under 

2 paragraph (1)(A), information submitted pursuant 

3 to subsection (b)(1)(B), the Secretary— 

4 (A) has the discretion to determine that 

5 such information does not warrant a for-cause 

6 price increase exemption; and 

7 (B) shall exclude from such consideration 

8 any information submitted by the applicable en9 tity threatening to curtail or limit production of 

10 the prescription drug if the Secretary does not 

11 grant an exemption from the application of the 

12 tax under section 4192 of the Internal Revenue 

13 Code of 1986. 

14 (e) INSPECTOR GENERAL REPORT TO INTERNAL

15 REVENUE SERVICE.— 

16 (1) IN GENERAL.—Subject to paragraph (3), 

17 not later than the last day in February of each year, 

18 the Inspector General shall transmit to the Internal 

19 Revenue Service a report on the findings of the In20 spector General with respect to the information the 

21 Inspector General received under subsection (b)(1) 

22 with respect to the preceding calendar year and the 

23 assessment carried out by the Inspector General 

24 under subsection (c)(1)(A) with respect to such in25 formation. 


lotter on DSKBCFDHB2PROD with BILLS
12 

•S 1369 IS

1 (2) CONTENTS.—The report transmitted under 

2 paragraph (1) shall include the following: 

3 (A) The information received under sub4 section (b)(1) with respect to the preceding cal5 endar year. 

6 (B) The price spikes identified under sub7 paragraph (A) of subsection (c)(2). 

8 (C) The price spike revenue determinations 

9 made under subparagraph (B)(i) of such sub10 section. 

11 (D) The determinations and assessments 

12 made under clauses (ii) and (iii) of subpara13 graph (B) of such subsection. 

14 (3) NOTICE AND OPPORTUNITY FOR HEAR15 ING.— 

16 (A) IN GENERAL.—No report shall be 

17 transmitted to the Internal Revenue Service 

18 under paragraph (1) in regards to a prescrip19 tion drug unless the Inspector General has pro20 vided the applicable entity with— 

21 (i) the assessment of such drug under 

22 subsection (c)(1)(A); and 

23 (ii) notice of their right to a hearing 

24 in regards to such assessment. 


lotter on DSKBCFDHB2PROD with BILLS
13 

•S 1369 IS

1 (B) NOTICE.—The notice required under 

2 subparagraph (A) shall be provided to the ap3 plicable entity not later than 30 days after com4 pletion of the assessment under subsection 

5 (c)(1)(A). 

6 (C) REQUEST FOR HEARING.—Subject to 

7 subparagraph (E), an applicable entity may re8 quest a hearing before the Secretary of Health 

9 and Human Services not later than 30 days 

10 after the date on which the notice under sub11 paragraph (B) is received. 

12 (D) COMPLETION OF HEARING.—In the 

13 case of an applicable entity which requests a 

14 hearing pursuant to subparagraph (C), the Sec15 retary of Health and Human Services shall, not 

16 later than 12 months after the date on which 

17 the assessment under subsection (c)(1)(A) was 

18 completed by the Inspector General— 

19 (i) make a final determination in re20 gards the accuracy of such assessment; 

21 and 

22 (ii) provide the report described in 

23 paragraph (2) to the Internal Revenue 

24 Service. 


lotter on DSKBCFDHB2PROD with BILLS
14 

•S 1369 IS

1 (E) LIMITATION.—An applicable entity 

2 may request a hearing under subparagraph (C) 

3 with respect to a particular prescription drug 

4 only once within a 5-year period. 

5 (4) PUBLICATION.— 

6 (A) IN GENERAL.—Not later than the last 

7 day in February of each year, subject to sub8 paragraph (B), the Inspector General shall 

9 make the report transmitted under paragraph 

10 (1) available to the public, including on the 

11 Internet website of the Inspector General, sub12 ject to subparagraph (B). 

13 (B) PROPRIETARY INFORMATION.—The 

14 Inspector General shall ensure that any infor15 mation made public in accordance with sub16 paragraph (A) excludes trade secrets and con17 fidential commercial information. 

18 (f) NOTIFICATION.—The Secretary of the Treasury, 

19 in conjunction with the Inspector General, shall notify, at 

20 such time and in such manner as the Secretary of the 

21 Treasury shall provide, each applicable entity in regard 

22 to any prescription drug which has been determined to 

23 have been subject to a price spike during the preceding 

24 calendar year and the amount of the tax imposed on such 


lotter on DSKBCFDHB2PROD with BILLS
15 

•S 1369 IS

1 applicable entity pursuant to section 4192 of the Internal 

2 Revenue Code of 1986. 

3 SEC. 3. EXCISE TAX ON PRESCRIPTION DRUGS SUBJECT TO 

4 PRICE SPIKES. 

5 (a) IN GENERAL.—Subchapter E of chapter 32 of the 

6 Internal Revenue Code of 1986 is amended by adding at 

7 the end the following new section: 

8 ‘‘SEC. 4192. PRESCRIPTION DRUGS SUBJECT TO PRICE 

9 SPIKES. 

10 ‘‘(a) IMPOSITION OF TAX.— 

11 ‘‘(1) IN GENERAL.—Subject to paragraph (3), 

12 for each taxable prescription drug sold by an appli13 cable entity during the calendar year, there is hereby 

14 imposed on such entity a tax equal to the greater 

15 of— 

16 ‘‘(A) the annual price spike tax for such 

17 prescription drug, or 

18 ‘‘(B) subject to paragraph (2), the cumu19 lative price spike tax for such prescription drug. 

20 ‘‘(2) LIMITATION.—In the case of a taxable 

21 prescription drug for which the applicable period (as 

22 determined under subsection (c)(2)(E)(i)) is less 

23 than 2 calendar years, the cumulative price spike tax 

24 shall not apply. 


lotter on DSKBCFDHB2PROD with BILLS
16 

•S 1369 IS

1 ‘‘(3) EXEMPTION.—For any calendar year in 

2 which the Secretary of Health and Human Services 

3 has provided an exemption for a taxable prescription 

4 drug pursuant to section 2(d) of the Stop Price 

5 Gouging Act, the amount of the tax determined 

6 under paragraph (1) for such drug or device for 

7 such calendar year shall be reduced to zero. 

8 ‘‘(b) ANNUAL PRICE SPIKE TAX.— 

9 ‘‘(1) IN GENERAL.—The amount of the annual 

10 price spike tax shall be equal to the applicable per11 centage of the price spike revenue received by the 

12 applicable entity on the sale of the taxable prescrip13 tion drug during the calendar year. 

14 ‘‘(2) APPLICABLE PERCENTAGE.—For purposes 

15 of paragraph (1), the applicable percentage shall be 

16 equal to— 

17 ‘‘(A) in the case of a taxable prescription 

18 drug which has been subject to a price spike 

19 percentage greater than the applicable price in20 crease allowance (as defined in section 

21 2(a)(6)(C) of the Stop Price Gouging Act) but 

22 less than 15 percent, 50 percent, 

23 ‘‘(B) in the case of a taxable prescription 

24 drug which has been subject to a price spike 


lotter on DSKBCFDHB2PROD with BILLS
17 

•S 1369 IS

1 percentage equal to or greater than 15 percent 

2 but less than 20 percent, 75 percent, and 

3 ‘‘(C) in the case of a taxable prescription 

4 drug which has been subject to a price spike 

5 percentage equal to or greater than 20 percent, 

6 100 percent. 

7 ‘‘(c) CUMULATIVE PRICE SPIKE TAX.— 

8 ‘‘(1) IN GENERAL.—The amount of the cumu9 lative price spike tax shall be equal to the applicable 

10 percentage of the cumulative price spike revenue re11 ceived by the applicable entity on the sale of the tax12 able prescription drug during the calendar year. 

13 ‘‘(2) APPLICABLE PERCENTAGE.— 

14 ‘‘(A) IN GENERAL.—For purposes of para15 graph (1), the applicable percentage shall be 

16 equal to— 

17 ‘‘(i) in the case of a taxable prescrip18 tion drug which has been subject to a cu19 mulative price spike percentage greater 

20 than the cumulative price increase allow21 ance but less than the first compounded 

22 percentage, 50 percent, 

23 ‘‘(ii) in the case of a taxable prescrip24 tion drug which has been subject to a cu25 mulative price spike percentage equal to or 


lotter on DSKBCFDHB2PROD with BILLS
18 

•S 1369 IS

1 greater than the first compounded percent2 age but less than the second compounded 

3 percentage, 75 percent, and 

4 ‘‘(iii) in the case of a taxable prescrip5 tion drug which has been subject to a cu6 mulative price spike percentage equal to or 

7 greater than the second compounded per8 centage, 100 percent. 

9 ‘‘(B) CUMULATIVE PRICE SPIKE PERCENT10 AGE.—The cumulative price spike percentage is 

11 the percentage (if any) by which— 

12 ‘‘(i) the average manufacturer price of 

13 the taxable prescription drug in commerce 

14 for the preceding calendar year, exceeds 

15 ‘‘(ii) the average manufacturer price 

16 of such prescription drug in commerce for 

17 the base year. 

18 ‘‘(C) CUMULATIVE PRICE INCREASE AL19 LOWANCE.—For purposes of clause (i) of sub20 paragraph (A), the cumulative price increase al21 lowance for any calendar year is the percentage 

22 (rounded to the nearest one-tenth of 1 percent) 

23 by which the medical care consumer price index 

24 detailed expenditure category for all urban con25 sumers (United States city average) for that 


lotter on DSKBCFDHB2PROD with BILLS
19 

•S 1369 IS

1 year exceeds such index for the preceding cal2 endar year. 

3 ‘‘(D) COMPOUNDED PERCENTAGES.—For 

4 purposes of subparagraph (A), the first com5 pounded percentage and second compounded 

6 percentage shall be determined in accordance 

7 with the following table: 

‘‘Number of years in applicable period 

First compounded 

percentage 

Second compounded 

percentage 

2 years .................................................................... 32.25 44.00

3 years .................................................................... 52.09 72.80

4 years .................................................................... 74.90 107.36

5 years .................................................................... 101.14 148.83. 

8 ‘‘(E) APPLICABLE PERIOD AND BASE

9 YEAR.— 

10 ‘‘(i) APPLICABLE PERIOD.—The appli11 cable period shall be the lesser of— 

12 ‘‘(I) the 5 preceding calendar 

13 years, 

14 ‘‘(II) all calendar years beginning 

15 after the date of enactment of this 

16 section, or 

17 ‘‘(III) all calendar years in which 

18 the taxable prescription drug was sold 

19 in commerce. 


lotter on DSKBCFDHB2PROD with BILLS
20 

•S 1369 IS

1 ‘‘(ii) BASE YEAR.—The base year 

2 shall be the calendar year immediately pre3 ceding the applicable period. 

4 ‘‘(3) CUMULATIVE PRICE SPIKE REVENUE.— 

5 For purposes of paragraph (1), the cumulative price 

6 spike revenue for any taxable prescription drug shall 

7 be an amount equal to— 

8 ‘‘(A) an amount equal to the product of— 

9 ‘‘(i) an amount (not less than zero) 

10 equal to— 

11 ‘‘(I) the average manufacturer 

12 price of such prescription drug in 

13 commerce for the preceding calendar 

14 year, minus 

15 ‘‘(II) the average manufacturer 

16 price of such prescription drug in 

17 commerce for the base year, and 

18 ‘‘(ii) the total number of units of such 

19 prescription drug which were sold in com20 merce in the preceding calendar year, 

21 minus 

22 ‘‘(B) an amount equal to the sum of the 

23 adjustment amounts, if any, determined under 

24 section 2(a)(7)(C) of the Stop Price Gouging 


lotter on DSKBCFDHB2PROD with BILLS
21 

•S 1369 IS

1 Act for each calendar year during the applicable 

2 period. 

3 ‘‘(d) DEFINITIONS.—For purposes of this section— 

4 ‘‘(1) TAXABLE PRESCRIPTION DRUG.—The 

5 term ‘taxable prescription drug’ means a prescrip6 tion drug (as defined in section 2(a)(5) of the Stop 

7 Price Gouging Act) which has been identified by the 

8 Inspector General of the Department of Health and 

9 Human Services, under section 2(c)(2)(A) of such 

10 Act, as being subject to a price spike. 

11 ‘‘(2) OTHER TERMS.—The terms ‘applicable en12 tity’, ‘average manufacturer price’, ‘price spike’, 

13 ‘price spike percentage’, and ‘price spike revenue’ 

14 have the same meaning given such terms under sec15 tion 2(a) of the Stop Price Gouging Act.’’. 

16 (b) CLERICAL AMENDMENTS.— 

17 (1) The heading of subchapter E of chapter 32 

18 of the Internal Revenue Code of 1986 is amended by 

19 striking ‘‘Medical Devices’’ and inserting ‘‘Cer20 tain Medical Devices and Prescription 

21 Drugs’’. 

22 (2) The table of subchapters for chapter 32 of 

23 such Code is amended by striking the item relating 

24 to subchapter E and inserting the following new 

25 item: 

‘‘SUBCHAPTER E. CERTAIN MEDICAL DEVICES AND PRESCRIPTION DRUGS’’. 


lotter on DSKBCFDHB2PROD with BILLS
22 

•S 1369 IS

1 (3) The table of sections for subchapter E of 

2 chapter 32 of such Code is amended by adding at 

3 the end the following new item: 

‘‘Sec. 4192. Prescription drugs subject to price spikes.’’. 

4 (c) EFFECTIVE DATE.—The amendments made by 

5 this section shall apply to sales after the date of the enact6 ment of this Act. 

7 SEC. 4. STUDY ON MONOPOLY MEDICAL PRODUCTS. 

8 (a) IN GENERAL.—The Comptroller General of the 

9 United States shall conduct a study that examines— 

10 (1) how drug manufacturers and health plans 

11 (including private insurers, the Medicare program, 

12 and State Medicaid programs) establish initial 

13 launch prices for newly approved drugs; and 

14 (2) alternative methods that have been pro15 posed for setting the price of new drugs. 

16 (b) STUDY OF SPECIFIC DRUGS.—As part of the 

17 study described in subsection (a), the Comptroller General 

18 shall examine drug pricing with respect to several drugs 

19 approved within the 5-year period immediately preceding 

20 the date of enactment of this Act and explore potential 

21 alternative approaches to establish new drug prices that 

22 could help make new drugs more affordable, better reflect 

23 the clinical value of such drugs in treating patients, and 

24 maintain incentives for innovation. 


lotter on DSKBCFDHB2PROD with BILLS
23 

•S 1369 IS

1 (c) FACTORS.—In conducting the study described in 

2 subsection (a), the Comptroller General shall consider— 

3 (1) what factors drug manufacturers and health 

4 plans consider in establishing initial launch prices; 

5 (2) how initial pricing decisions by drug manu6 facturers and health plans affect costs and use of 

7 services for patients and public programs such as 

8 the Medicare and Medicaid programs; 

9 (3) efforts by health plans to limit costs, includ10 ing through benefit design or coverage limitations; 

11 (4) how prices change in the first few years fol12 lowing a new drug’s launch; and 

13 (5) recommendations manufacturers, health 

14 plans, and other experts have for alternative ap15 proaches to establishing new drug prices and the 

16 benefits and challenges associated with such alter17 native approaches. 

18 SEC. 5. REVENUES COLLECTED. 

19 There are authorized to be appropriated to the Sec20 retary of Health and Human Services such sums as are 

21 equal to any increase in revenue to the Treasury by reason 

22 of the provisions of this Act or the amendments made by 

23 this Act for the purposes of increasing amounts available 


lotter on DSKBCFDHB2PROD with BILLS
24 

•S 1369 IS

1 to the National Institutes of Health for research and de2 velopment of drugs. 

Æ 


lotter on DSKBCFDHB2PROD with BILLS